HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jehn, M. Articles by Guallar, E. Search for Related Content PubMed PubMed Citation Articles by Jehn, M. Articles by Guallar, E. Social Bookmarking                What's this?

Serum Ferritin and Risk of the Metabolic Syndrome in U.S. Adults

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Address correspondence and reprint requests to Eliseo Guallar, MD, DrPH, Welch Center for Prevention, Epidemiology & Clinical Research, 2024 E. Monument St., Suite 2-639, Baltimore, MD 21205. E-mail: eguallar{at}jhsph.edu

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVE—We examined the relationship among iron stores, the metabolic syndrome, and insulin resistance.

RESEARCH DESIGN AND METHODS—We conducted a cross-sectional study of 6,044 adults >20 years of age who participated in the Third National Health and Nutrition Examination Survey. Metabolic syndrome was defined as the presence of at least three of the following: elevated blood pressure, low HDL cholesterol, elevated serum triglycerides, elevated plasma glucose, and abdominal obesity. Insulin resistance was estimated using homeostasis model assessment (for insulin resistance), fasting insulin, and triglyceride–to–HDL cholesterol ratio.

RESULTS—After excluding individuals with likely hemochromatosis, mean serum ferritin values in premenopausal women, postmenopausal women, and men were 33.6, 93.4, and 139.9 µg/l, respectively. Metabolic syndrome was more common in those with the highest compared with the lowest levels of serum ferritin in premenopausal women (14.9 vs. 6.4%, P = 0.002), postmenopausal women (47.5 vs. 28.2%, P < 0.001), and men (27.3 vs. 13.8%, P < 0.001). Insulin resistance also increased across quartiles of serum ferritin for men and postmenopausal women and persisted after adjustment for age, race/ethnicity, C-reactive protein, smoking, alcohol intake, and BMI.

CONCLUSIONS—Elevated iron stores were positively associated with the prevalence of the metabolic syndrome and with insulin resistance.

Abbreviations: ALT, alanine aminotranferase • AST, aspartate aminotransferase • CRP, C-reactive protein • HOMA-IR, homeostasis model assessment for insulin resistance • NHANES III, Third National Health and Nutrition Examination Survey

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
There is increasing evidence that moderately elevated body iron stores, below levels commonly found in genetic hemochromatosis, may be associated with adverse health outcomes. Elevated serum ferritin levels independently predicted incident type 2 diabetes in prospective studies in apparently healthy men and women (1,2). In cross-sectional studies, elevated ferritin levels have been associated with hypertension (3), dyslipidemia (4,5), elevated fasting insulin and blood glucose (6), and central adiposity (7). The association between elevated iron stores and the metabolic syndrome, however, has been less well explored (8).

Although the mechanisms for the potential effect of iron on the risk of metabolic syndrome are unclear, it has been hypothesized that elevated iron stores may interfere with hepatic insulin extraction leading to peripheral hyperinsulinemia (9,10). Others have suggested that iron may catalyze the formation of hydroxyl radicals, which contribute to the development of insulin resistance (11,12).

We hypothesized that the metabolic syndrome would be more common in those with moderately elevated serum ferritin levels. To test this hypothesis, we conducted a cross-sectional analysis using representative data from the general U.S. population.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
The Third National Health and Nutrition Examination Survey (NHANES III) was conducted by the National Center for Health Statistics between 1988 and 1994. The survey was a multistage nationwide probability sample of the civilian, noninstitutionalized U.S. population. The study design included a home interview and a detailed clinical evaluation (13).

The present analysis was restricted to NHANES III participants 20 years of age, who were not pregnant or nursing at the time of the examination and who were randomly assigned to receive a morning examination (n = 7,907). We excluded individuals who had fasted <9 h at the time of the examination (n = 600), who had received treatment for anemia within the last 3 months (n = 186), with known current hepatitis C infection (n = 184), who had donated blood within the last 4 months (n = 195), or who had probable hemochromatosis based on abnormal values of multiple iron parameters (men: serum iron >190 µg/dl, serum ferritin >300 µg/l, and transferrin saturation >60%; women: serum iron >175 µg/dl, serum ferritin >200 µg/l, and transferrin saturation >60%) (n = 24) (14). Because some individuals met more than one exclusion criterion, the total number eligible for the study was 6,646. Individuals missing measurements for serum ferritin, fasting insulin, or any of the components of the metabolic syndrome were further excluded in the analysis (n = 602). Therefore, the final analytical sample consisted of 6,044 individuals.

Data from NHANES III were collected by household interview followed by a detailed physical examination conducted at a mobile examination center or at the participant’s home. Information on age, race/ethnicity, education, smoking history, alcohol intake, and use of antihypertensive and diabetes medications was collected during the interview. Menopausal status was defined as self-reported cessation of menstruation or hysterectomy. The average of all available blood pressure readings taken during the home interview and physical examination (up to six) was used in the analysis. Waist circumference was measured by a trained technician to the nearest 0.1 cm in a horizontal plane at the level of the high point of the iliac crest at minimal respiration. BMI was calculated as weight in kilograms divided by the square of height in meters. Alcohol intake was categorized as never, zero to two alcoholic drinks per day, and more than two alcoholic drinks per day based on self-reported average over the past 12 months. Smoking was categorized as current, former, and never.

NHANES laboratory procedures and quality control have been published previously (15). Serum ferritin was measured on fasting blood samples using a single-incubation two-site immunoradiometric assay (Bio-Rad Laboratories, Hercules, CA). The interassay coefficients of variation ranged from 4 to 6%. Plasma glucose was measured using a modified hexokinase enzymatic reference method (COBAS MIRA; Roche Diagnostics Laboratory Systems, Indianapolis, IN). Serum insulin was measured using the Pharmacia Insulin radioimmunoassay kit (Pharmacia Diagnostics, Uppsala, Sweden). Serum triglycerides and HDL cholesterol were measured enzymatically (Boehringer Mannheim Diagnostics, Indianapolis, IN). Alanine aminotranferase (ALT) and aspartate aminotransferase (AST) were assayed using the -ketoglutarate reaction. Serum C-reactive protein (CRP) concentration was determined using latex-enhanced nephelometry with a limit of detection of 0.21 mg/dl.

The metabolic syndrome was defined as the presence of three or more of the following criteria set forth by the National Cholesterol Education Program Adult Treatment Panel III guidelines (16): 1) elevated blood pressure (average systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmHg) or current blood pressure medication use, 2) low HDL cholesterol (<1.036 mmol/l in men and <1.295 mmol/l in women), 3) elevated serum triglycerides (1.695 mmol/l), 4) elevated fasting plasma glucose (6.105 mmol/l) or current antidiabetes medication use, and 5) abdominal obesity (waist circumference 102 cm in men and 88 cm in women). Diabetes was defined as a fasting plasma glucose value >7.0 mmol/l or current use of antidiabetes medication.

Insulin resistance was determined using the homeostasis model assessment (HOMA) estimate of insulin resistance (HOMA-IR = fasting insulin [µU/ml] x fasting glucose [mmol/l]/22.5) (17), fasting insulin level, and the ratio of triglyceride to HDL cholesterol.

All analyses were performed separately for men, premenopausal women, and postmenopausal women, including calculation of specific quartiles of serum ferritin. Serum ferritin values were right skewed and were log transformed. Odds ratios for the prevalence of the metabolic syndrome and its components were calculated for quartiles of serum ferritin using logistic regression. Tests for trend across quartiles were computed by including a variable with the median value for each quartile as a continuous variable in the logistic regression models. All models were adjusted for age, race/ethnicity, BMI, CRP, smoking, and alcohol intake. Statistical analyses were performed using STATA (version 8.1; College Station, TX) "svy" commands to account for complex survey design and included sampling weights to provide nationally representative prevalence estimates.

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Mean levels of serum ferritin were significantly lower in premenopausal women 33.6 µg/l (95% CI 31.5–35.8) compared with postmenopausal women 93.4 µg/l (87.9–99.2) and lower in postmenopausal women compared with men 139.9 µg/l (133.6–146.6). The prevalence of the metabolic syndrome was 10.2% in premenopausal women, 27.8% in postmenopausal women, and 17.5% in men.

In all three groups, the highest prevalence of the metabolic syndrome occurred in the highest quartile of serum ferritin (Table 1). The prevalence of elevated blood pressure, elevated plasma glucose, elevated triglycerides, and abdominal adiposity all increased significantly with increasing serum ferritin in men and postmenopausal women. In premenopausal women, the prevalence of elevated triglycerides and abdominal adiposity also increased with increasing serum ferritin. For all three groups, the greater the number of metabolic syndrome components present, the greater the serum ferritin level (Fig. 1).

View larger version (21K): [in this window] [in a new window]   Figure 1— Mean serum ferritin levels by the number of metabolic syndrome components. Geometric mean values of serum ferritin are shown for premenopausal women (black bar), postmenopausal women (white bar), and men (gray bar). Error bars represent upper 95% CI. The trend of increasing mean ferritin values across categories of metabolic syndrome components was significant for all three groups (P < 0.05).

Insulin resistance
Mean values of estimated insulin resistance were calculated by quartile of serum ferritin (Table 3). This analysis was restricted to individuals without diabetes. We did not observe any consistent association between HOMA-IR or fasting insulin with serum ferritin in premenopausal women. We did observe a trend of increasing insulin resistance (HOMA-IR, fasting insulin, and triglyceride-to-HDL ratio) with increasing serum ferritin in both postmenopausal women and men. In Table 4, we present the multivariate-adjusted ratio of insulin resistance measures for the second, third, and fourth quartiles of serum ferritin compared with the first. Similar to the unadjusted analyses, the ratio of insulin resistance values increased with increasing quartiles of serum ferritin in men and postmenopausal women. For example, levels of the triglyceride-to-HDL ratio were 21% higher in the highest quartile of serum ferritin compared with the lowest quartile of serum ferritin for men. In postmenopausal women, the observed association between insulin resistance and ferritin appeared to follow a j-shaped pattern in which values were slightly elevated in the first quartile, lower in the second quartile, and then increased in the third and fourth quartiles.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

Several cross-sectional studies have previously examined the association between iron stores and individual metabolic cardiovascular risk factors, including hypertension (3), dyslipidemia (4,5), elevated fasting insulin and blood glucose (6), and central adiposity (7). Our results are consistent with the previous literature and extend these observations to include the metabolic syndrome. The explanation for the observed j-shaped association between ferritin levels and markers of insulin resistance in postmenopausal women is unknown. It is possible that a carbohydrate-rich, protein-poor diet, which may lead to iron deficiency, may also contribute to insulin resistance (19).

Several lines of evidence support the association between elevated iron stores and insulin resistance. Type 2 diabetes is commonly observed in patients with hemochromatosis, a group with demonstrated iron overload (20). Second, serum ferritin levels correlated with various measures of insulin sensitivity in several different populations, including individuals without diabetes (6,21), individuals with diabetes (22), women with gestational diabetes (23), and patients with thalassemia (24). Third, a small intervention study of phlebotomy in patients with type 2 diabetes resulted in improved insulin sensitivity (22). Finally, two prospective studies have shown an association between elevated iron stores and incident diabetes (1,2). These studies were conducted in Finnish men (1) and U.S. nurses (2), and both provide evidence that elevated ferritin levels precede the development of diabetes.

It is unclear whether elevated iron stores may simply be another marker of insulin resistance or whether elevated iron stores may contribute to the pathogenesis of altered metabolic states. Iron is a transition metal capable of causing oxidative tissue damage by catalyzing the formation of free radicals (12). Iron overload may contribute to insulin resistance through mechanisms related to both reduced extraction of insulin and impaired insulin secretion (25). Results of oral glucose tolerance tests in patients with hemochromatosis have suggested that hepatic iron overload results in impaired insulin extraction (10). Others have suggested that iron deposition in pancreatic ß-cells may also impair insulin secretion in more advanced states of iron overload (25).

Serum ferritin is a widely used marker of iron status in epidemiological studies (20) and accurately reflects differences in body iron stores by age and sex (26). However, serum ferritin is an acute-phase reactant and may be artificially elevated in the presence of inflammation (18). We attempted to minimize this potential source of confounding by adjusting for CRP and by excluding those individuals with suspected inflammation, infection, and liver disease in sensitivity analyses; however, we cannot rule out residual confounding by other inflammatory conditions. Similarly, we cannot rule out residual confounding by unmeasured factors that may be related both to the prevalence of the metabolic syndrome and to ferritin levels. A further limitation of this study is the cross-sectional design, which prevents us from making inferences about the directionality of the associations. Although there is increasing evidence to suggest that iron may influence glucose metabolism, it is possible that glucose metabolism may also influence body iron stores. Insulin, possibly through the activation of hypoxia-inducible factor-1, may stimulate the production of erythropoietin, thus increasing the efficiency of iron absorption (27).

In summary, moderately elevated iron levels were associated with an increased prevalence of the metabolic syndrome and markers of insulin resistance. These associations were evident at moderately elevated iron levels, below levels associated with hemochromatosis. Given the high prevalence of elevated iron stores, especially in older ages, prospective studies are needed to determine whether moderately elevated iron stores precede the development of insulin resistance and contribute to the increased risk associated with it.

	Acknowledgments

 
M.J. was supported by National Heart, Lung, and Blood Institute Training Grant 5T32-HL-007024-27.

	Footnotes

 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication May 11, 2004. Accepted for publication June 23, 2004.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K: Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 317:727, 1998[Free Full Text]
   
2. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB: Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291:711–717, 2004[Abstract/Free Full Text]
   
3. Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, Mariani R, Mancia G: Increased serum ferritin is common in men with essential hypertension. J Hypertens 20:1513–1518, 2002[Medline]
   
4. Halle M, Konig D, Berg A, Keul J, Baumstark MW: Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis 128:235–240, 1997[Medline]
   
5. Williams MJ, Poulton R, Williams S: Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis 165:179–184, 2002[Medline]
   
6. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT: Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care 20:426–428, 1997[Abstract]
   
7. Gillum RF: Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men: the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 25:639–645, 2001[Medline]
   
8. Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J: Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 21:62–68, 1998[Abstract]
   
9. Ferrannini E: Insulin resistance, iron, and the liver. Lancet 355:2181–2182, 2000[Medline]
   
10. Niederau C, Berger M, Stremmel W, Starke A, Strohmeyer G, Ebert R, Siegel E, Creutzfeldt W: Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 26:441–444, 1984[Medline]
    
11. Ford ES, Cogswell ME: Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 22:1978–1983, 1999[Abstract/Free Full Text]
    
12. Wolff SP: Diabetes mellitus and free radicals: free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 49:642–652, 1993[Abstract/Free Full Text]
    
13. National Center for Health Statistics: Plan and Operation of the Third National Health and Nutrition Examination Survey. Vol. 11. Washington, DC, Vital Health Statistics, 1994, p. 1–407
    
14. Fairbanks VF: Laboratory testing for iron status. Hosp Pract (Off Ed) 26 (Suppl. 3):17–24, 1991
    
15. National Center for Health Statistics: The Third National Health and Nutrition Examination Survey (NHANES III 1998–1994). References Manuals and Reports (CD-ROM). Hyattsville, MD, National Center for Health Statistics, 1996
    
16. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD, National Institutes of Health, 2001, (NIH publ. no. 01-3670)
    
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 1985[Medline]
    
18. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454, 1999[Free Full Text]
    
19. Pinhas-Hamiel O, Newfield RS, Koren I, Agmon A, Lilos P, Phillip M: Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes Relat Metab Disord 27:416–418, 2003[Medline]
    
20. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA: Practice guideline development task force of the College of American Pathologists: hereditary hemochromatosis. Clin Chim Acta 245:139–200, 1996[Medline]
    
21. Haap M, Fritsche A, Mensing H, Haring H, Stumvoll M: Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med 139:869–870, 2003[Free Full Text]
    
22. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W: Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and ß-cell function. Diabetes 51:1000–1004, 2002[Abstract/Free Full Text]
    
23. Lao TT, Chan PL, Tam KF: Gestational diabetes mellitus in the last trimester: a feature of maternal iron excess? Diabet Med 18:218–223, 2001[Medline]
    
24. Cario H, Holl RW, Debatin KM, Kohne E: Disproportionately elevated fasting proinsulin levels in normoglycemic patients with thalassemia major are correlated to the degree of iron overload. Horm Res 59:73–78, 2003[Medline]
    
25. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF: Potential role of increased iron stores in diabetes. Am J Med Sci 325:332–339, 2003[Medline]
    
26. Zacharski L, Ornstein D, Woloshin S, Schwartz L: Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 140:98–104, 2000[Medline]
    
27. McCarty MF: Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1. Med Hypotheses 61:567–573, 2003[Medline]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				T. M.E. Davis, J. Beilby, W. A. Davis, J. K. Olynyk, G. P. Jeffrey, E. Rossi, C. Boyder, and D. G. Bruce Prevalence, Characteristics, and Prognostic Significance of HFE Gene Mutations in Type 2 Diabetes: The Fremantle Diabetes Study Diabetes Care, September 1, 2008; 31(9): 1795 - 1801. [Abstract] [Full Text] [PDF]

				J. Huang, J. S. Gabrielsen, R. C. Cooksey, B. Luo, L. G. Boros, D. L. Jones, H. A. Jouihan, Y. Soesanto, L. Knecht, M. W. Hazel, et al. Increased Glucose Disposal and AMP-dependent Kinase Signaling in a Mouse Model of Hemochromatosis J. Biol. Chem., December 28, 2007; 282(52): 37501 - 37507. [Abstract] [Full Text] [PDF]

				M. Luque-Ramirez, F. Alvarez-Blasco, J. I. Botella-Carretero, R. Sanchon, J. L. San Millan, and H. F. Escobar-Morreale Increased Body Iron Stores of Obese Women With Polycystic Ovary Syndrome Are a Consequence of Insulin Resistance and Hyperinsulinism and Are Not a Result of Reduced Menstrual Losses Diabetes Care, September 1, 2007; 30(9): 2309 - 2313. [Abstract] [Full Text] [PDF]

				L. Valenti, E. A. Pulixi, P. Arosio, L. Cremonesi, G. Biasiotto, P. Dongiovanni, M. Maggioni, S. Fargion, and A. L. Fracanzani Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis Haematologica, August 1, 2007; 92(8): 1037 - 1042. [Abstract] [Full Text] [PDF]

				I. S. Vari, B. Balkau, A. Kettaneh, P. Andre, J. Tichet, F. Fumeron, E. Caces, M. Marre, B. Grandchamp, P. Ducimetiere, et al. Ferritin and Transferrin Are Associated With Metabolic Syndrome Abnormalities and Their Change Over Time in a General Population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Diabetes Care, July 1, 2007; 30(7): 1795 - 1801. [Abstract] [Full Text] [PDF]

				S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah The Role of Iron in Diabetes and Its Complications Diabetes Care, July 1, 2007; 30(7): 1926 - 1933. [Full Text] [PDF]

				M. L. Jehn, E. Guallar, J. M. Clark, D. Couper, B. B. Duncan, C. M. Ballantyne, R. C. Hoogeveen, Z. L. Harris, and J. S. Pankow A Prospective Study of Plasma Ferritin Level and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study Am. J. Epidemiol., May 1, 2007; 165(9): 1047 - 1054. [Abstract] [Full Text] [PDF]

				C.-J. Tsai, M. F Leitzmann, W. C Willett, and E. L Giovannucci Heme and non-heme iron consumption and risk of gallstone disease in men Am. J. Clinical Nutrition, February 1, 2007; 85(2): 518 - 522. [Abstract] [Full Text] [PDF]

				S. M. Grundy Gamma-Glutamyl Transferase: Another Biomarker for Metabolic Syndrome and Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 4 - 7. [Full Text] [PDF]

				R. T. Acton, J. C. Barton, L. V. Passmore, P. C. Adams, M. R. Speechley, F. W. Dawkins, P. Sholinsky, D. M. Reboussin, G. D. McLaren, E. L. Harris, et al. Relationships of Serum Ferritin, Transferrin Saturation, and HFE Mutations and Self-Reported Diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Diabetes Care, September 1, 2006; 29(9): 2084 - 2089. [Abstract] [Full Text] [PDF]

				F. Fumeron, F. Pean, F. Driss, B. Balkau, J. Tichet, M. Marre, B. Grandchamp, and for the DESIR Study Group Ferritin and Transferrin Are Both Predictive of the Onset of Hyperglycemia in Men and Women Over 3 Years: The Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care, September 1, 2006; 29(9): 2090 - 2094. [Abstract] [Full Text] [PDF]

				Z. Shi, X. Hu, B. Yuan, X. Pan, H. E. Meyer, and G. Holmboe-Ottesen Association Between Serum Ferritin, Hemoglobin, Iron Intake, and Diabetes in Adults in Jiangsu, China Diabetes Care, August 1, 2006; 29(8): 1878 - 1883. [Abstract] [Full Text] [PDF]

				M.-C. Vantyghem, I. Fajardy, F. Dhondt, C. Girardot, M. D'Herbomez, P.-M. Danze, J. Rousseaux, and J.-L. Wemeau Phenotype and HFE genotype in a population with abnormal iron markers recruited from an Endocrinology Department. Eur. J. Endocrinol., June 1, 2006; 154(6): 835 - 841. [Abstract] [Full Text] [PDF]

				S. Rajpathak, J. Ma, J. Manson, W. C. Willett, and F. B. Hu Iron Intake and the Risk of Type 2 Diabetes in Women: A prospective cohort study. Diabetes Care, June 1, 2006; 29(6): 1370 - 1376. [Abstract] [Full Text] [PDF]

				D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches Clin. Chem., June 1, 2006; 52(6): 950 - 968. [Abstract] [Full Text] [PDF]

				C E Wrede, R Buettner, L C Bollheimer, J Scholmerich, K-D Palitzsch, and C Hellerbrand Association between serum ferritin and the insulin resistance syndrome in a representative population Eur. J. Endocrinol., February 1, 2006; 154(2): 333 - 340. [Abstract] [Full Text] [PDF]

				L. Mascitelli and F. Pezzetta Dairy Intake, Reduced Body Iron Stores, and the Development of Type 2 Diabetes Mellitus Arch Intern Med, November 14, 2005; 165(20): 2433 - 2434. [Full Text] [PDF]

				T. Iwasaki, A. Nakajima, M. Yoneda, Y. Yamada, K. Mukasa, K. Fujita, N. Fujisawa, K. Wada, and Y. Terauchi Serum Ferritin Is Associated With Visceral Fat Area and Subcutaneous Fat Area Diabetes Care, October 1, 2005; 28(10): 2486 - 2491. [Abstract] [Full Text] [PDF]

				H. F. Escobar-Morreale, M. Luque-Ramirez, F. Alvarez-Blasco, J. I. Botella-Carretero, J. Sancho, and J. L. San Millan Body Iron Stores Are Increased in Overweight and Obese Women With Polycystic Ovary Syndrome Diabetes Care, August 1, 2005; 28(8): 2042 - 2044. [Full Text] [PDF]

				C. Bozzini, D. Girelli, O. Olivieri, N. Martinelli, A. Bassi, G. De Matteis, I. Tenuti, V. Lotto, S. Friso, F. Pizzolo, et al. Prevalence of Body Iron Excess in the Metabolic Syndrome Diabetes Care, August 1, 2005; 28(8): 2061 - 2063. [Full Text] [PDF]

				L. Mascitelli and F. Pezzetta Serum Ferritin Levels in Patients With Nonalcoholic Fatty Liver Disease Arch Intern Med, May 9, 2005; 165(9): 1070 - 1070. [Full Text] [PDF]

				H. J. Kim, S. K. Kim, and B. S. Cha Serum Ferritin Levels in Patients With Nonalcoholic Fatty Liver Disease--Reply Arch Intern Med, May 9, 2005; 165(9): 1070 - 1070. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jehn, M. Articles by Guallar, E. Search for Related Content PubMed PubMed Citation Articles by Jehn, M. Articles by Guallar, E. Social Bookmarking                What's this?